Similar articles for PMID: 19133981

Year	Number of Results
1986	1
1988	2
1989	2
1997	2
1998	1
2000	2
2001	1
2002	2
2003	2
2004	3
2005	10
2006	1
2007	6
2008	7
2009	7
2010	6
2011	7
2012	8
2013	4
2014	3
2015	4
2016	3
2020	2
2024	0

1

Decitabine is an effective treatment of idiopathic myelofibrosis.

Danilov AV, Relias V, Feeney DM, Miller KB. Danilov AV, et al. Br J Haematol. 2009 Apr;145(1):131-2. doi: 10.1111/j.1365-2141.2008.07541.x. Epub 2008 Dec 26. Br J Haematol. 2009. PMID: 19133981 Free article. No abstract available.

2

Decitabine.

Daskalakis M, Blagitko-Dorfs N, Hackanson B. Daskalakis M, et al. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. Recent Results Cancer Res. 2010. PMID: 20072836 Review.

3

Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.

Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV. Liu Y, et al. Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23647061 No abstract available.

4

Decitabine. MGI Pharma Inc/SuperGen Inc.

Arthur C. Arthur C. IDrugs. 2004 Dec;7(12):1113-32. IDrugs. 2004. PMID: 15599805 Review.

5

Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.

Steensma DP, Friday BB. Steensma DP, et al. Leuk Lymphoma. 2007 Aug;48(8):1628-9. doi: 10.1080/10428190701435267. Leuk Lymphoma. 2007. PMID: 17701595 No abstract available.

6

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Aribi A, et al. Cancer. 2007 Feb 15;109(4):713-7. doi: 10.1002/cncr.22457. Cancer. 2007. PMID: 17219444 Free article.

7

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ. Silverman LR, et al. Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. doi: 10.1038/ncponc0347. Nat Clin Pract Oncol. 2005. PMID: 16341236 Review.

8

DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.

Lübbert M. Lübbert M. Curr Top Microbiol Immunol. 2000;249:135-64. doi: 10.1007/978-3-642-59696-4_9. Curr Top Microbiol Immunol. 2000. PMID: 10802943 Review. No abstract available.

9

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.

Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV. Tabarroki A, et al. Leuk Lymphoma. 2015 Feb;56(2):497-9. doi: 10.3109/10428194.2014.916805. Epub 2014 May 27. Leuk Lymphoma. 2015. PMID: 24766471 No abstract available.

10

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.

Carella AM. Carella AM. Eur J Haematol. 2015 Jun;94(6):463. doi: 10.1111/ejh.12521. Epub 2015 Mar 16. Eur J Haematol. 2015. PMID: 25702976 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year